•
Mar 31, 2024

OptimizeRx Q1 2024 Earnings Report

OptimizeRx's Q1 2024 financial results were reported, showing revenue growth and increased gross profit.

Key Takeaways

OptimizeRx reported Q1 2024 revenue of $19.7 million, a 51% increase year-over-year. Gross profit increased by 64% to $12.2 million, with a gross margin of 62%. The company won 9 DAAP deals during the quarter and reiterated its full-year 2024 revenue guidance of at least $100 million and Adjusted EBITDA of at least $11 million.

Q1 revenue reached $19.7 million, a 51% increase year-over-year.

Gross profit increased by 64% year-over-year to $12.2 million, with a gross margin of 62%.

The company secured 9 DAAP wins in Q1.

Net Revenue Retention came in at 116% for the first quarter.

Total Revenue
$19.7M
Previous year: $13M
+51.4%
EPS
-$0.11
Previous year: -$0.09
+22.2%
Avg revenue per top 20 pharma
$2.59M
Top 20 pharma revenue share
66%
Net revenue retention
116%
Gross Profit
$12.2M
Previous year: $7.43M
+64.1%
Cash and Equivalents
$15.2M
Previous year: $16.4M
-7.7%
Free Cash Flow
$2.09M
Previous year: -$115K
-1920.6%
Total Assets
$176M
Previous year: $132M
+33.9%

OptimizeRx

OptimizeRx

Forward Guidance

The Company is reiterating its 2024 guidance and expects revenue to be at least $100 million with an Adjusted EBITDA of at least $11 million.